Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
23 January 2019 | Story Charlene Stanley | Photo Charlene Stanley
Michele Middle
Michelle Middle, CMO of Farmovs, looks forward to expanding their operations after the UFS acquired 100% shareholding in 2018.

In medical research, there are NO shortcuts.

The journey of a new medicine from lab to pharmacy shelf takes on average at least 10 years.

Michelle Middle’s journey from young medical graduate starting her first job at FARMOVS to becoming the company’s Chief Medical Officer, was more than twice that long. It was a journey that systematically and adequately equipped her to now Co-captain this flagship enterprise through its biggest challenge yet.

Michelle remembers how Farmovs started in 1974 as a research centre in the Department of Pharmacology. After graduating as medical doctor, she joined Farmovs in 1993, shortly before they moved to their current extensive facilities just south of the Sasol Library.

In 2000, international Clinical Research Organization (CRO) giant Parexel acquired a 70% shareholding, and the name changed to Farmovs-Parexel.

“Parexel really invested a lot in infrastructure and technology, bringing facilities here on par with the best in the world,” says Michelle.

Her own journey in medical research took her to George and later to the US and UK, where she held various international executive leadership positions in international companies.

When the UFS acquired a 100% shareholding in Farmovs earlier this year, she came full circle, as she returned to Bloemfontein to spearhead the expansion of patient studies in collaboration with the Faculty of Health Sciences.

“The opportunities we have here are really enormous,” says an excited Michelle.

“We are the only university in the country with this kind of infrastructure. Apart from our state-of-the-art bioanalytical lab, we also have facilities to accommodate close to 100 research participants. We now have 45 years’ experience in advanced medical research, plus established international clients. We can provide pharmaceutical companies with basically everything they need to develop new medicines.”

Another exciting development is that they are expanding their clinical-trial patient population next year from healthy individuals to people suffering from a host of chronic conditions.

“While they are part of our clinical trials, patients gain valuable insight in their own conditions. We also sometimes pick up underlying medical issues they were not even aware of,” says Michelle.

The 150 Farmovs staff members range from doctors and nurses, to technologists, medical writers, and managers. While not technically part of the university staff, they form a valued part of the Bloemfontein Campus community.

News Archive

UFS cardiac team does pioneering work
2017-10-29

Description: ' 000 Cardiac Pioneers Tags: Cardiac Pioneers 

“With the use of endomyocardial biopsies, the team hopes to treat viruses unique
to Southern Africa, as well as other underlying causes of dilated cardiomyopathy.”

Photo: iStock

Members of the University of the Free State’s (UFS) Cardiac team had various achievements at national and international level this year. The Robert WM Frater Cardiovascular Research Centre in the Faculty of Health Sciences has commenced with a pioneering research project regarding idiopathic dilating cardiomyopathy.

With an Afrocentric research focus, Prof Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS and Head of the Frater Centre, describes dilating cardiomyopathy as a heart muscle disease that is quite common, particularly among people of African descent. The disease weakens the heart muscle, which in turn leads to heart failure.

“To date there is no curable treatment for this condition, and 50% of patients who have shown heart failure, died within a period of five years. The causes of this condition have been unknown in the majority of patients. But over the past few years major strides have been made, where virus infections of the heart muscle, or myocarditis, have been identified as a possible underlying cause. Various genetic diseases are also linked to it,” says Prof Smit.

According to Prof Mokoali Makotoko, Head of the Department of Cardiology, more than 1 500 new cases of heart failure are identified at the Universitas Academic Hospital annually, of which approximately 30% are attributed to cardiomyopathy. “With the use of endomyocardial biopsies, the team hopes to treat viruses unique to Southern Africa, as well as other underlying causes of dilated cardiomyopathy.”

The study is a project that flows from Prof Makotoko’s PhD. The project is being run with Prof Heinz-Peter Schultheiss of the Charité University and the Institute for Cardiac Diagnostics and Therapy in Berlin, Germany.

 "More than 1 500 new cases of heart failure are identified at the Universitas Academic Hospital annually, of which approximately 30% are attributed to cardiomyopathy."

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept